Download PDF
Pneumologie 2006; 60(8): 493-508
DOI: 10.1055/s-2006-944265
Serie: Pharmakologische Therapie
© Georg Thieme Verlag Stuttgart · New York

Pharmakologische Therapie des Bronchialkarzinom

Teil I: StandardsPharmacologic Treatment of Bronchial CancerPart 1: StandardsM.  Serke1
  • 1Zentrum für Pneumologie und Thoraxchirurgie, Heckeshorn, Helios-Klinikum Emil-von-Behring, Berlin
Further Information

Publication History

Publication Date:
24 August 2006 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Im letzten Jahrzehnt hat sich der Stellenwert der Chemotherapie beim Bronchialkarzinom gewandelt. Sie wurde wesentlicher Bestandteil im multimodalen Therapiekonzept für fast alle Stadien des NSCLC und bleibt Basis jeder Therapie beim SCLC. Neue Therapieprinzipien mit neuen Angriffspunkten befinden sich in klinischer Prüfung, von denen wir Fortschritte im Überleben erhoffen. Stadienabhängige Grundlagen der Therapieentscheidung zum Procedere werden dargestellt. Anschließend werden die einzelnen Zytostatika vorgestellt.

Abstract

In the last decade there have been important innovations in the treatment of lung tumors. New combined modality therapies are becoming standard and require a network of cooperating partners. New therapeutic agents are under investigation that will hopefully improve the outcome of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
Principles of chemotherapy in non-small cell und small cell lung cancer depending on stage and combination in multimodal regimens are shown. In the second part single drugs are described with their typical effects and side effects from the viewpoint of a clinician. A following part II will discuss new “targeted” biologicals.

Literatur

  • 1 Non-small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials.  BMJ. 1995;  311 899-909
    Google Scholar
  • 2 Souquet P J, Chauvin F, Boissel J P. et al . Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis.  Lancet. 1993;  342 19-21
    CrossrefPubMedGoogle Scholar
  • 3 Cullen M H, Billingham L J, Woodroffe C M. et al . Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.  J Clin Oncol. 1999;  17 3188-3194
    PubMedGoogle Scholar
  • 4 American Society of Clinical Oncology . Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer.  J Clin Oncol. 1997;  15 2996-3018
    PubMedGoogle Scholar
  • 5 Arriagada R, Bergman B, Dunant A. et al . Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall-cell lung cancer.  N Eng J med. 2004;  350 351-360
    CrossrefPubMedGoogle Scholar
  • 6 Winton T, Livingston R, Johnson D. et al . Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.  N Engl J Med. 2005;  352 2589-2597
    CrossrefPubMedGoogle Scholar
  • 7 Douillard J Y, Rosell R, De Lena M. et al . ANITA. A prospective randomized study of adjuvant chemotherapy with navelbine and cisplatin in completely resected non small cell lung cancer.  ProcASCO. 2005;  7013
    PubMedGoogle Scholar
  • 8 Dillmann R O, Herndon J, Seagran S L. et al . Improved survival in stage III NSCLC: seven-year follow up of CALGB 8433 trial.  J Natl Cancer Inst. 1996;  88 1210-1215
    CrossrefPubMedGoogle Scholar
  • 9 Vokes E E, Herndon J E, Crawford J. et al . Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer. Cancer and leucemia group B study 9431.  J Clin Oncol. 2002;  20 4191-4198
    CrossrefPubMedGoogle Scholar
  • 10 Hansen H H. Management of small cell cancer of the lung.  Lancet. 1992;  339 846-849
    CrossrefPubMedGoogle Scholar
  • 11 Sandler A B, Nemunaitis J, Denham C. et al . Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.  J Clin Oncol. 2000;  18 122-130
    PubMedGoogle Scholar
  • 12 Wozniak A J, Crowley J J, Balcerzak S P. et al . Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study.  J Clin Oncol. 1998;  16 2459-2465
    PubMedGoogle Scholar
  • 13 Gatzemeier U, Pawel J von, Gottfried M. et al . Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.  J Clin Oncol. 2000;  18 3390-3399
    PubMedGoogle Scholar
  • 14 Lilienbaum R C, Langenberg P, Dickersin K. Single agent chemotherapy versus combination chemotherapy in patients with advanced NSCLC: A meta-analysis of response, toxi-city and survival.  Cancer. 1998;  82 116-126
    CrossrefPubMedGoogle Scholar
  • 15 Hotta K, Matsuo K, Ueoka H. et al . Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non small-cell lung cancer.  J Clin Oncol. 2004;  22 3852-3853
    CrossrefPubMedGoogle Scholar
  • 16 Serke M, Schönfeld N, Loddenkemper R. Neue Zytostatika in der Therapie des Nicht-kleinzelligen Bronchialkarzinoms.  Pneumologie. 1998;  52 333-337
    PubMedGoogle Scholar
  • 17 Schiller J H, Harrington D, Belani C P. et al . Comparison of 4 chemotherapy regimens for advanced non-small cell lung cancer.  N Engl J Med. 2002;  346 92-98
    CrossrefPubMedGoogle Scholar
  • 18 Cardenal F, Lopez-Cabrerizo P, Anton A. et al . Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic NSCLC.  J Clin Oncol. 1999;  17 12-18
    PubMedGoogle Scholar
  • 19 Le Chevaliier T, Brisgand D, Douillard J Y. et al . Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients.  J Clin Oncol. 1994;  12 360-367
    PubMedGoogle Scholar
  • 20 GSMO Guideline Task Force . ESMO Minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC).  Annals Oncology. 2005;  16 (S1) i28-29
    PubMedGoogle Scholar
  • 21 Eckhardt J R, Pawel J von, Papai Z. et al . An open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naïve patients with extensive-disease small-cell lung cancer.  J Clin Oncol. 2006;  24 2044-2051
    CrossrefPubMedGoogle Scholar
  • 22 Noda K, Nishiwaki Y, Kawahara M. et al . Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.  N Eng J Med. 2002;  346 85-91
    CrossrefPubMedGoogle Scholar
  • 23 Hanna N, Shepherd F A, Fossella F V. et al . Randomized phase III trial of Pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy.  J Clin Oncol. 2004;  22 1589-1597
    CrossrefPubMedGoogle Scholar
  • 24 D'Addario G, Pintilie M, Leighl N. et al . Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer. A meta-analysis of the published literature.  J Clin Oncol. 2005;  23 2926-2936
    CrossrefPubMedGoogle Scholar
  • 25 Pujol J L, Barlesi F, Daures J P. Should chemotherapy combinations for advanced NSCLC be platinum-based? A meta-analysis of phase III randomized trials.  Lung Cancer. 2006;  51 335-345
    CrossrefPubMedGoogle Scholar
  • 26 Huhn D. Alkylantien. In: Huhn D, Herrmann R (Hrsg). Medikamentöse Therapie maligner Erkrankungen, 3. Aufl. Stuttgart 2005: Fischer Verlag
    Google Scholar
  • 27 Efferth T, Osieka R. Antineoplastische Substanzen: Substanzklassen und Wirkmechanismen. In: Schmoll, Höffken, Possinger (Hrsg). Kompendium internistische Onkologie, 4. Aufl. Heidelberg: Springer Verlag 2005
    Google Scholar
  • 28 Colvin O M, Friedman H S. Alkylating agents. In: De Vita, Hellman, Rosenberg (ed). Cancer. Principles and Practice of Oncology, 7th ed. Philadelphia: Lippincott Williams + Wilkins 2005
    Google Scholar
  • 29 Johnson S W, O'Dwyer P J. Cisplatin and its analogues. In: De Vita, Hellman, Rosenberg (ed). Cancer. Principles and Practice of Oncology, 7th ed. Philadelphia: Lippincott Williams + Wilkins 2005
    Google Scholar
  • 30 Bokemeyer C, Sökler M, Schmoll H J. et al .Begleittherapie bei Cisplatin. In: Schmoll, Höffken, Possinger (Hrsg). Kompendium internistische Onkologie, 4. Aufl. Heidelberg: Springer Verlag
    Google Scholar
  • 31 Takimoto C H. Topoisomerase interactive agents. In: De Vita, Hellman, Rosenberg (ed). Principles and Practice of Oncology, 7th ed. Philadelphia: Lippincott Williams + Wilkins 2005
    Google Scholar
  • 32 Possinger K. Anthracycline. In: Huhn D, Herrmann R (Hrsg). Medikamentöse Therapie maligner Erkrankungen, 3. Aufl. Stuttgart: Fischer Verlag
    Google Scholar
  • 33 Rowinski E K, Tolcher A W. Antimicrotubule agents. In: De Vita, Hellman, Rosenberg (ed). Cancer. Principles and Practice of Oncology, 7th ed. Philadelphia: Lippincott Williams + Wilkins 2005
    Google Scholar
  • 34 Kummar S, Noronha V, Chu E. Antimetabolites. In: De Vita, Hellman, Rosenberg (ed). Cancer. Principles and Practice of Oncology, 7th ed. Philadelphia: Lippincott Williams + Wilkins 2005
    Google Scholar
  • 35 Crino L, Scagliotti G V, DeMarinos F. et al . Gemcitabine and cisplatin versus Mitomycin, ifosfamide and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study if the Italian lung cancer project.  J Clin Oncol. 1999;  17 (11) 3522-3530
    PubMedGoogle Scholar
  • 36 Gridelli C, Gallo C, Shepherd F A. et al . Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.  J Clin Oncol. 2003;  21 3025-3034
    CrossrefPubMedGoogle Scholar
  • 37 Kosmidis P, Mylonakis N, Nicolaides C. et al . Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial.  J Clin Oncol. 2002;  20 3578-3585
    CrossrefPubMedGoogle Scholar
  • 38 Souquet P J, Tan E H, Pereira R. et al . Glob-1: a prospective randomized clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamid-cisplatin in metastatic non small-cell lung caner patients.  Ann Oncol. 1857;  13 (12) 61
    PubMedGoogle Scholar
  • 39 Schütte W, Nagel S, Blankenburg T. et al . Phase III study of Second-Line Chemotherapy for Advanced NSCLC with weekly compared with 3-weekly Docetaxel.  J Clin Oncol. 2005;  23 8389-8395
    CrossrefPubMedGoogle Scholar

Dr. Monika Serke

ltd. OÄ Pneumologie · Helios-Klinikum Emil-von-Behring · Zentrum f. Pneumologie und Thoraxchirurgie, Heckeshorn

Zum Heckeshorn 33

14109 Berlin

Email: m.serke@behring.helios-kliniken.de

      >